Abbott Laboratories (ABT) director logs 301 stock equivalent units in Form 4

Rhea-AI Filing Summary

Abbott Laboratories director Michael F. Roman reported routine equity-based compensation activity. On 12/31/2025, he acquired 301 stock equivalent units tied to Abbott common shares at a listed price of $125.29 per share equivalent. After this transaction, he held 5,882 derivative securities, reported as directly owned.

According to the disclosure, these stock equivalent units represent director fees credited to a stock equivalent unit account and are generally paid in cash at age 65 or upon retirement from the board. The units are structured to earn the same return as if the fees were invested in Abbott shares, and the balance also reflects units acquired through a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roman Michael F

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	(1)	12/31/2025		A		301		(1)	(1)	Common Shares	301	$125.29	5,882(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ Michael F. Roman by Jessica H. Paik, Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abbott Laboratories (ABT) disclose in this Form 4 for Michael F. Roman?

The filing shows that director Michael F. Roman acquired 301 stock equivalent units tied to Abbott Laboratories common shares on 12/31/2025 as part of his director compensation.

How many derivative securities does Michael F. Roman own after this transaction at Abbott (ABT)?

Following the reported transaction, Michael F. Roman beneficially owns 5,882 derivative securities, reported as directly held.

What are the stock equivalent units reported by Abbott Laboratories (ABT) for its director?

The stock equivalent units represent director fees credited to a stock equivalent unit account, generally paid in cash at age 65 or upon retirement, and they earn the same return as if invested in Abbott shares.

What was the price associated with the stock equivalent units in the Abbott (ABT) Form 4?

The transaction lists a price of $125.29 per stock equivalent unit, corresponding to the value tied to the underlying Abbott common shares.

Does the Abbott (ABT) filing mention dividend reinvestment for the director’s units?

Yes. The explanation states that the reported balance of stock equivalent units includes units acquired pursuant to a dividend reinvestment feature.

What is Michael F. Roman’s relationship to Abbott Laboratories (ABT)?

He is reported as a Director of Abbott Laboratories, filing the Form 4 as a single reporting person.